Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 RA patient demographic data, blood inflammatory parameters and treatment profile

From: Rheumatoid peripheral blood phagocytes are primed for activation but have impaired Fc-mediated generation of reactive oxygen species

Sex Age ESR
(mm/h)
CRP
(mg/l)
Hb
(g/dl)
Platelets
(× 109/l)
WBC
(× 109/l)
Lymphocytes
Neutrophils (× 109/l)
(× 109/) Medication
M 71 58 60 12.7 351 10.3 7.8 1.7 Diclofenac
M 53 93 36 10.3 417 10.5 8.4 1.5 Methotrexate
M 78 57 74 12.4 422 7.8 5.5 1.5 -
M 62 16 17 14.1 207 6.1 3.5 2 -
F 61 37 - 12.3 261 6.1 3.9 1.6 Leflunomide
F 75 61 77 11.6 246 6.5 5.3 0.8 -
F 42 27 17 13.7 356 12.7 10.4 1.8 -
F 63 49 45 11.1 359 5.8 4.7 0.6 Clarithromycin
F 56 20 - 13.9 263 8 5 2.5 Methotrexate, prednisolone, Losec, perindopril, Sinemet, aspirin
F 82 37 - 12 195 8.2 5.6 1.8 -
F 63 41 41 11.4 309 9.8 9.6 3.3 -
F 57 - 13.9 - - - - - Methotrexate, prednisolone, (depo-medrone)
F 76 57 72 11 244 7.7 6.3 0.9 -
F 49 - - 11.4 204 7.2 4.4 2.5 Azothioprine, meloxicam
F 45 48 - 12.9 259 7.4 5.6 1.3 Methotrexate, indomethacin
F 92 1 - 13.9 232 9.6 7.5 0.9 Penicillamine
F 56 18 - 13.7 481 8.2 5.1 1.9 Methotrexate, folic acid, prednisolone, Vioxx, antihypertensive treatment
F 44 7 - 13.2 241 7.1 4.8 1.3 Leflunomide
F 68 12 5 12.7 284 6.9 4.6 1.7 Azothioprine, prednisolone, alendronate, thyroxine, Losec
F 56 18 23 13.7 481 8.2 5.1 1.9 -
F 78 12 5 - - - - - -
F 52 16 11 - - - - - Leflunomide
  1. Eighteen patients (4 male, 14 female; age 62.6 ± 13.4 years (mean ± SD) with active synovitis and receiving a range of disease-modifying anti-rheumatic agents were recruited into the study. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hb, haemoglobin; WBC, white blood cells.